Vaxcyte (PCVX) Asset Writedowns and Impairment (2022)

Vaxcyte (PCVX) reported Asset Writedowns and Impairment of -$13000.0 for Q4 2022, down 108.33% quarter-over-quarter from $156000.0 in Q2 2022.

Vaxcyte (PCVX) Asset Writedowns and Impairment (2022) Analysis & Trends

Vaxcyte (PCVX) has 1 years of Asset Writedowns and Impairment data on file, last reported at -$13000.0 in Q4 2022.

Asset Writedowns and Impairment for Q4 2022 came in at -$13000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2023 was -$13000.0 (down 106.1% YoY), and the FY2022 annual result was $200000.0, changed N/A from the prior year.
Asset Writedowns and Impairment eased to -$13000.0 in Q4 2022 per PCVX's latest filing, from $156000.0 in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $156000.0 in Q2 2022 and troughed at -$13000.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn
9	Abivax	91.71 Bn	91.71 Bn	-
10	Vaxcyte	6.34 Bn	6.34 Bn	-

Download Data